Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.52 |
| ▸ | GMNN | O75496 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | MTOR | P42345 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CETP | P11597 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | UBE2N | P61088 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12731069 | 1.00 | LMNA (0.52) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL177887 | 1.00 | LMNA (0.52) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL16653364 | 0.92 | CYP2D6 (0.61) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL11159 | 0.92 | CYP2D6 (0.61) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL5549292 | 0.92 | CYP2D6 (0.61) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL12198626 | 0.92 | CYP2D6 (0.61) | LMNACYP2D6SPHK1GMNNPOLB | |
| Bicarbonate SCHEMBL29012522 | 0.91 | CYP2D6 (0.45) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL25243382 | 0.90 | LMNA (0.65) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL1964037 | 0.90 | LMNA (0.65) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL10571108 | 0.90 | LMNA (0.65) | LMNACYP2D6SPHK1GMNNPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1426 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388896-A1 | COMPOSITION AND METHODS FOR TRANSGENE INSERTION | CELYNTRA THERAPEUTICS SA (BE) | 2025-12-25 | — | — | US | claimed |
| EP-4621488-A1 | RINSE SOLUTION COMPOSITION FOR EXTREME ULTRAVIOLET PHOTOLITHOGRAPHY AND PATTERN FORMATION METHOD USING SAME | Ycchem Co., Ltd. (KR) | 2025-09-24 | — | — | EP | claimed |
| US-20250275536-A1 | Antimicrobial Composition | KAMER, Patrick (CH) | 2025-09-04 | — | — | US | claimed |
| US-20250236813-A1 | RINSE SOLUTION COMPOSITION FOR EXTREME ULTRAVIOLET PHOTOLITHOGRAPHY AND PATTERN FORMATION METHOD USING SAME | YCCHEM CO., LTD. (KR) | 2025-07-24 | — | — | US | claimed |
| US-20250186364-A1 | COMBINATION OF ANTISPASMODIC AND ANESTHETIC AGENTS FOR TOPICAL PRODUCTS AND THEIR METHOD OF USE | PRIMA INNOVATIONS, LLC | 2025-06-12 | — | — | US | claimed |
| US-20250186365-A1 | COMBINATION OF ANTISPASMODIC AND OSMOTIC AGENTS FOR TOPICAL PRODUCTS AND METHOD OF USE THEREOF | PRIMA INNOVATIONS, LLC | 2025-06-12 | — | — | US | claimed |
| CN-120019333-A | Flushing liquid composition for extreme ultraviolet lithography and pattern forming method using same | YC化学制品株式会社 | 2025-05-16 | — | — | CN | claimed |
| CN-120005137-A | Microcapsule closed type polybasic isocyanate, medium, grating and preparation method and equipment | 珠海莫界科技有限公司 | 2025-05-16 | — | — | CN | claimed |
| EP-4518653-A1 | ANTIMICROBIAL COMPOSITION | Kamer, Patrick (CH) | 2025-03-12 | — | — | EP | claimed |
| CN-119320309-A | Preparation method and application of 2, 4-polysubstituted-1, 3-cyclobutanediol | 万华化学集团股份有限公司 | 2025-01-17 | — | — | CN | claimed |
| EP-1100326-A1 | BASE-TRIGGERED RELEASE MICROCAPSULES | Syngenta Limited (GB) | 2001-05-23 | — | — | EP | claimed |
| EP-1069131-A1 | Methods for separating particulate substrates from solution while minimizing particle loss | QIAGEN GmbH (DE) | 2001-01-17 | — | — | EP | claimed |
| EP-1006121-A1 | A universal polymer support for the synthesis of oligonucleotides | Council of Scientific and Industrial Research (IN) | 2000-06-07 | — | — | EP | claimed |
| WO-2000005951-A1 | BASE-TRIGGERED RELEASE MICROCAPSULES | SYNGENTA LIMITED (GB) | 2000-02-10 | — | — | WO | claimed |
| EP-0957903-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | Codon Pharmaceuticals, Inc. (US) | 1999-11-24 | — | — | EP | claimed |
| US-5990177-A | CYCLIC AND ACYCLIC MONO-, DI- AND TRIALCOHOLS AS STIMULANTS TO TREAT DISEASES MEDIATED BY DEFICIENCIES IN THE NITRIC OXIDE/CYCLIC GUANOSINE MONOPHOSPHATE/PROTEIN KINASE G SIGNAL TRANSDUCTION PATHWAY; CARDIOVASCULAR; SKIN; NERVOUS SYSTEM | CODON PHARMACEUTICALS, INC. (US) | 1999-11-23 | — | — | US | claimed |
| US-5942608-A | REACTING ALKANEDIOL WITH 4,48-DIMETHOXY TRITYL CHLORIDE; THEN ALKANOIC ACID HALIDE; IMMOBILIZATION | Council of Sciemtific & Industrial Research and Department of Biotechnology (IN) | 1999-08-24 | — | — | US | claimed |
| WO-1998055085-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | CODON PHARMACEUTICALS, INC. (US) | 1998-12-10 | — | — | WO | claimed |
| WO-1998011882-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | CODON PHARMACEUTICALS, INC. (US) | 1998-03-26 | — | — | WO | claimed |
| US-5030550-A | Containing a basic compound and a nonionic surfactant containing oxyethylene and oxypropylene groups | FUJI PHOTO FILM CO., LTD. (JP) | 1991-07-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388896-A1 | COMPOSITION AND METHODS FOR TRANSGENE INSERTION | GDA, XPA, ERCC2 | LMNA 34/4885CYP2D6 4839/4885SPHK1 3741/4885 |
| US-20250275536-A1 | Antimicrobial Composition | CUTA, POLR1C, PIK3C3 | LMNA 2754/4885CYP2D6 2614/4885SPHK1 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.